Weekly Ozempic for insulin-dependent double diabetes
Part of Hormones & metabolism clinical trials.
This trial tests whether a weekly injection called Ozempic (a GLP-1 medicine) can improve blood sugar control in adults who have type 1 diabetes plus higher-risk features for type 2 diabetes. If you qualify, the study will compare Ozempic against standard care to see if it helps your diabetes outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) and can give written consent
- You have confirmed type 1 diabetes, with C-peptide below the lab cutoff
- You were diagnosed before age 35
- You’ve used “optimized” insulin for at least 1 year (pump or multiple injections) and got training to adjust doses
- Your BMI is at least 27, but not above 40
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a weekly injection of tirzepatide (a drug that helps with blood sugar and weight) can improve glucose control in adults with type 1 diabetes who already use an automated insulin pump. It may help you if your blood sugar is not at target despite using a pump.
This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.
This study tracks how Ozempic works and whether it stays safe for people with type 2 diabetes in everyday clinic care in Korea. You join because your doctor decides you should start Ozempic, and the study mainly monitors outcomes.
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
Hear when a new Double Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.